|
IMVIF
|
This interview with Matasar (in charge of VITALIZE trial) looks pretty...
|
|
IMVIF
|
It is here: https://www.imv-inc.com/the-dpx-platform/scientific-publications...
|
|
IMVIF
|
The ESMO presentation (the PDF is already ay IMV website) was just a...
|
|
IMVIF
|
If you go to page 19 of last Corporate presentation, you will find, on the...
|
|
IMVIF
|
"IfI can just settle that and then I'll have Jeremy take a little...
|
|
IMVIF
|
Following the data published yesterday at IMV's site, there were just 13...
|
|
IMVIF
|
Following the data published yesterday at IMV's site, there were just 13...
|
|
IMVIF
|
ORR: 29'4% (CR 11'8%, PR: 17'6%) mOS (Overall Survival): not...
|
|
IMVIF
|
Today it was announced that next results (bladder and MSI-H from the Basket...
|
|
IMVIF
|
DPX (100% of patients): 19'9 months Mirvetuximab (60% of patients...
|
|
IMVIF
|
The point is to get approved with tipline data of ORR, much before the study...
|
|
IMVIF
|
https://clinicaltrials.gov/ct2/show/study/NCT04920617?term=Maveropepimut&...
|
|
IMVIF
|
https://www.businesswire.com/news/home/20210609005202/en/
|
|
IMVIF
|
I said liver and MSI-H and should have said bladder, MSI-H and, may be, liver...
|
|
IMVIF
|
We are, if DLBCL data are replicated in Phase 2b, just about one year from...
|
|
IMVIF
|
Days ago Sutro Biopharma updated results of Stro-002 in ovarian (last were...
|
|
IMVIF
|
If they update (asannounced) ovarian and Basket Trial, with proper data, and...
|
|
IMVIF
|
Don't get your point...: Selected Upcoming Milestones Maveropepimut-S Q2...
|
|
IMVIF
|
Most recently Dr. Kalos served as Executive Vice President and Head of R&...
|
|
IMVIF
|
IMVs Lead Immunotherapy to be Investigated in Breast Cancer Study will...
|